Medical systems virology

At the global level, influenza virus (IAV) is considered a major health threat. kainov_03.jpgIt causes  global flu pandemics and contributes to seasonal epidemics. Different treatment and prevention options have been developed; however, these are insufficient in the face of recent IAV outbreaks.

Our goal is

  • to improve human health during IAV outbreaks

Our specific aims are:

  • to determine the principles that govern IAV-host interactions;
  • to develop inhibitors targeting IAV-host interactions;
  • to find genetic markers of individual susceptibility for IAV infections.

Group Members

  • Anastasina Maria, MSc, grad student, HBGS fellow
  • Jalovaara Petri, MA, trainee
  • Kainov Denis, PI, FIMM-EMBL group leader, docent, editor Journal of Proteolysis

Recent publications

Denisova OV, Soderholm S, Virtanen S, Von Schantz C, Bychkov D, Desloovere J, Theisen LL, Tynell J, Ikonen N, Vashchinkina E, Nyman TA, Matikainen S, Kallioniemi O, Julkunen I, Muller CP, Saelens X, Verkhusha VV, Kainov DE. Akt inhibitor MK2206 blocks pH1N1 influenza  virus infection in vitro. Antimicrob Agents Chemother. Accepted.

Lakspere T, Kallio-Kokko H, Kantele H, Mattila P, Almusa H, Kainov D, Kakkola L. Full-genome sequences of influenza H3N2 strains isolated from Finnish patients during 2012-2013 epidemic season. March/April 2014 2:e00039-14; doi:10.1128/genomeA.00039-14

Lakspere T, Tynell J, Kaloinen M, Vanlede M, Parsons A, Ikonen N, Kallio-Kokko H, Kantele H, Mattila P, Almusa H, Julkunen I, Kainov D, Kakkola L. Full-genome sequences of influenza A(H1N1)pdm09 viruses isolated from Finnish patients during 2009-2013. Genome Announc. 2014. 2. pii: e01004-13. doi: 10.1128/genomeA.01004-13.

Anastasina M, Terenin I, Butcher SJ, Kainov DE. A technique to increase protein yields in a rabbit reticulocyte lysate translation system. BioTechniques. 2014. 56:36-39.

Bimbo LM, Denisova OV, Mäkilä E, De Brabande JK, Hirvonen J, Salonen J, Kakkola L, Kainov DE, Santos HA. Inhibition of influenza A virus infection by saliphenylhalamide loaded silicon nanoparticles. ACS Nano. 2013. 7:6884-93

Kakkola L, Denisova OV, Tynell J, Viiliäinen J, Ysenbaert T, Matos R, Nagaraj A, Ohman T, Kuivanen S, Paavilainen H, Feng L, Yadav B, Julkunen I, Vapalahti O, Hukkanen V, Stenman J, Aittokallio T, Verschuren E, Ojala PM, Nyman T, Saelens X, Kainov DE. Anticancer compound ABT-263 accelerates apoptosis in virus infected cells and imbalances cytokine production  and lowers survival rates of infected mice. Cell Death Dis. 2013. 4, e742.

Smura T, Kakkola L, Blomqvist S, Klemola P, Parsons A, Kallio-Kokko H, Savolainen-Kopra C, Kainov D, Roivainen M. Molecular evolution and epidemiology of echovirus 6 in Finland. Infect Genet Evol. 2013. 16C:234-247.

Denisova OV, Kakkola L, Feng L, Stenman J, Nagaraj A, Lampe J, Yadav B, Aittokallio T, Kaukinen P, Ahola T, Kuivanen S, Vapalahti O, Kantele A, Tynell J, Julkunen I, Kallio-Kokko H, Paavilainen H, Hukkanen V, Elliott RM, De Brabander JK, Saelens X, and Kainov DE. Obatoclax, saliphenylhalamide and gemcitabine inhibitit influenza A virus infection. J Biol Chem. 2012. 287: 35324-32.

Feng L, Lintula S, Ho TH, Anastasina M, Paju A, Haglund C, Stenman UH,  Hotakainen K, Orpana A, Kainov D, Stenman J. Technique for strand-specific gene-expression analysis and monitoring of primer-independent cDNA synthesis in reverse transcription. BioTechniques. 2012. 52: 263-270.

Mueller KH, Kakkola L, Nagaraj AS, Cheltsov AV, Anastasina M, Kainov DE.  Emerging cellular targets for influenza antiviral agents. Trends Pharmacol Sci. 2012. 33: 89-99

 

wsn no inh 6hpi tom-gfp bad-mcher 60x overlay.tif

Funding

Jane and Aatos Erkko Foundation, Academy of Finland, HBGS

Contact

+358 50 415 5460; denis.kainov@helsinki.fi